Genscript Biotech Stock (OTC:GNNSF), Trade Ideas

GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.

GENSCRIPT BIOTECH CRP ORD by Genscript Biotech Corp

Genscript Biotech Corp

<a target="_blank" href="https://www.benzinga.com/news/24/01/36672636/rivian-revs-up-options-now-lease-r1s-suv-alongside-r1t-truck" rel="noreferrer noopener">Rivian Automotive Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)&nbsp;looks like&nbsp;it&#8217;s&nbsp;scheduled&nbsp;to open a new dealership in&nbsp;Tesla&#8216;s home state of Texas next month.&nbsp;
What Happened: The new space in Austin&nbsp;is set&nbsp;to open on May 24, according to its Google Business listing.
The dealership, as per the map data, seems to be located off South Congress Avenue in Austin, about 14 miles from <a href="https://www.benzinga.com/news/23/10/35141523/rivian-closing-the-gap-with-tesla-in-premium-ev-market-what-data-reveals" target="_blank" rel="noreferrer noopener">Tesla&#8217;s gigafactory</a>. Rivian already has dealerships with service centers in Austin, Dallas, and Houston.
Rivian did not immediately respond to Benzinga&#8216;s request for confirmation.
<figure class="wp-block-image size-full"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19024903/Screenshot-2024-04-19-at-12.18.53%E2%80%AFPM.png" alt="" class="wp-image-299318" /></figure>
Why It Matters: Rivian &#8220;spaces,&#8221; as they call them, are dealerships where customers can interact with the company&#8217;s lineup. The company already has dealerships across Colorado, Illinois, California, and New York.
Irvine, California-based Rivian first announced&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/02/37279528/tesla-ceo-elon-musk-says-rivian-exec-team-needs-to-live-in-the-factory-or-they-will-die" rel="noreferrer noopener">the Austin dealership</a>&nbsp;in June 2023. The 10,000-square-foot space will have a rooftop patio with city views and direct access to the Lady Bird Lake biking and running trail.
Rivian Takes Aim At Tesla&#8217;s Dominance: Both Tesla and Rivian offer electric SUVs and pickup trucks. Tesla&#8217;s Cybertruck competes with the Rivian R1T in the pickup segment, while the Rivian R1S SUV rivals Tesla&#8217;s Model X. 
Tesla CEO&nbsp;Elon Musk&nbsp;previously cast doubt on Rivian&#8217;s long-term viability, citing potential financial struggles.&nbsp;
The EV maker lost nearly $43,372 per vehicle delivered in the last quarter of 2023,&nbsp;but this&nbsp;is a significant improvement from prior quarters.&nbsp;
The company aims to achieve gross margin profitability by the end of 2024.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="http://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:&nbsp;<a href="https://www.benzinga.com/news/24/04/38285714/no-more-inventory-discounts-on-tesla-cars-as-ceo-elon-musk-says-sales-system-has-turned-complex-and" target="_blank" rel="noreferrer noopener">No More Inventory Discounts On Tesla Cars As CEO Elon Musk Says Sales System Has Turned ‘Complex And Inefficient'</a>

News

Tech

RIVN

Rivian's Newest Dealership In Texas Will Be Just 14 Miles From Tesla's Gigafactory, Google Data Shows

&nbsp;This deficiency will be considered by the Hearings Panel (the &quot;Panel&quot;) at a hearing that has been scheduled for April 25, 2024 (the &quot;Hearing&quot;) to address the Company&#39;s other current deficiencies.
As previously reported on May 8, 2023, due to the resignation of one of the Company&#39;s board members from its Board of Directors and therefore its Audit Committee on April 12, 2023, the Company no longer complied with the Audit Committee Requirements. Pursuant to Listing Rule 5605(c)(4), Nasdaq provided the Company a cure period to regain compliance with the Audit Committee Requirements, which ended on April 12, 2024.

BRSH

Brüush Oral Care Receives Additional Delisting Threat Over Audit Committee Non-Compliance

Biophytis SA (Nasdaq CM:BPTS)(PARIS:<a class="ticker" href="https://www.benzinga.com/stock/ALBPS#PARIS">ALBPS</a>), (&quot;Biophytis&quot; or the &quot;Company&quot;), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio of its American Depositary Shares (the &quot;ADSs&quot;) to Biophytis ordinary shares (the &quot;Shares&quot;) from one ADS representing 100 Shares, to one ADS representing 4,000 Shares (the &quot;Ratio Change&quot;). The effective date of the Ratio Change (the &quot;Effective Date&quot;) is expected to be April 23, 2024.

BPTS

PARIS:ALBPS

Biophytis Announces ADR Ratio Change: From 100 To 4,000 Shares Per ADS, Effective April 23

CNBC&#8217;s Jim Cramer warned that the market hasn&#8217;t found its bottom, advising against buying the dip. Tom Lee of Fundstrat echoed this caution, urging investors to hold off on purchasing stocks, anticipating a forthcoming wave of selling that could signal a bottom in the weeks ahead.
What Happened: Cramer, during his show &#8220;Mad Money,&#8221; suggested that the market is still in a downward trend, <a href="https://www.cnbc.com/2024/04/18/jim-cramer-says-the-market-hasnt-reached-a-real-bottom-yet.html">reported</a> CNBC. He cautioned investors to refrain from buying at the start of the session, stating that this is not the right move. 
Meanwhile, Lee cautioned that the recent surge in the VIX, the market&#8217;s volatility gauge, could prompt further selling, adding to the short-term pressure on stocks, <a href="https://markets.businessinsider.com/news/stocks/stock-market-outlook-sp500-bottom-buy-the-dip-sell-fundstrat-2024-4">reported</a> Business Insider. 
&#8220;While we normally like to buy dips, as we said earlier this week, the surge in the VIX says we gotta take buying the dip extra slowly,&#8221; Lee said in a video sent to clients on Thursday.
Despite this, Lee suggested that a buying opportunity might emerge soon, as the market seems poised to bottom out, with positive catalysts such as robust corporate earnings growth and potential Fed rate cuts still in play.
&#8220;I think there&#8217;s a widespread belief that you can still buy the dip. That&#8217;s been the right move ever since long-term interest rates peaked back in October,&#8221; he said. &#8220;Now, though, buying the dip is the quintessential wrong thing to do.&#8221;
Cramer pointed out that there are not enough companies with &#8220;brown shoots,&#8221; or disappointing earnings. He also highlighted the unpredictable patterns of market leaders such as Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), and NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), suggesting that investors should not assume that they have reached the bottom.
According to Cramer, the market requires a &#8220;vicious open,&#8221; followed by a &#8220;crescendo&#8221; moment, to reach a lasting bottom. He noted that the S&amp;P 500 has seen green intraday before closing lower each day this week.
Lee predicted that the market could hit a trough within the next month, provided that the Middle East conflict does not escalate further, volatility eases, and investors slow their pace of selling. He also forecasted that the S&amp;P 500 could reach 5,200 by the end of the year, with a best-case scenario of 5,500 or higher.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38293168/macro-guru-raoul-pal-says-80-of-his-crypto-investment-is-in-this-ethereum-rival-and-i-have?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Macro Guru Raoul Pal Says 80% Of His Crypto Investment Is In This Ethereum Rival: &#8216;And I Have 1% In Stupid S&#x2A;&#x2A;t Like Dogwifhat, Dogecoin And Bonk&#8217;</a>
Why It Matters: Cramer&#8217;s warning comes after he outlined potential factors that could lead to further market decline in a previous show. He advised investors to be cautious about their buying and selling decisions, <a href="https://www.benzinga.com/markets/equities/24/04/38306086/jim-cramer-explains-what-could-trigger-further-market-decline-if-you-want-to-get-out-go-ahead">stating</a>, &#8220;If you want to get out, go ahead.&#8221;
Despite recent concerns, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38284811/wall-street-experts-dismiss-rate-cut-fears-middle-east-tensions-predict-bull-market">Wall Street veterans</a> are confident that the bull market will persist, citing a robust U.S. economy and the potential of artificial intelligence (AI) as key drivers. The U.S. stock market experienced a recent downturn due to escalating tensions in the Middle East and apprehensions about monetary policy.
Earlier in April, Lee had <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38214726/fundstrats-tom-lee-encourages-investors-to-seize-market-dip-amid-inflation-concerns">encouraged investors to seize the market dip</a> following an inflation-induced sell-off, suggesting that a potential June rate cut was still on the table. However, his recent cautionary advice suggests a shift in the market dynamics.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38303079/most-s-p-500-stocks-no-longer-trade-above-50-day-average-healthy-pullback-or-is-the?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Most S&amp;P 500 Stocks No Longer Trade Above 50-Day Average: Healthy Pullback Or Is The Bull Market Over?</a>
Image Via Shutterstock
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Kaustubh Bagalkote</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/topic/kaustubh-bagalkote" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Equities

Markets

AAPL

NVDA

TSLA

Buying The Dip? Jim Cramer And Tom Lee Warn Market Hasn't Hit Rock Bottom Yet: 'Quintessential Wrong Thing To Do'

Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) has declared that it will no longer disclose its subscriber count every quarter, hinting at a potential deceleration in user growth.
What Happened: Netflix&#8217;s unexpected decision led to a dip in the company&#8217;s stock, Reuters last Friday. The streaming giant added 9.3 million new subscribers in Q1, nearly twice the predicted number. 
By the end of March, Netflix had a worldwide subscriber base of 269.6 million, marking a year-over-year growth of 16.0%. However, the company will stop revealing subscriber additions each quarter from Q1 2025, choosing to announce them only when significant milestones are achieved.
Co-CEO Greg Peters stated, &#8220;This change is really motivated by wanting to focus on what we see are the key metrics that we think matter most to business.&#8221;
Analysts fear that this move could unsettle investors and make it difficult for Wall Street to model the company&#8217;s business.
See Also: <a href="https://www.benzinga.com/news/24/04/38286236/once-trumper-scaramucci-warns-re-electing-ex-president-would-result-in-american-fascism-and-be-very?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Once-Trumper&#8217; Scaramucci Warns Re-Electing Ex-President Would Result In &#8216;American Fascism&#8217; And Be &#8216;Very Bad&#8217; For Business: &#8216;He Wants To Be North American Autocrat&#8217;</a>
Why It Matters: This decision follows <a href="https://www.benzinga.com/news/earnings/24/04/38324337/netflix-q1-earnings-highlights-revenue-beat-eps-beat-9-33-million-paid-subs-added-ad-tier-plan-upda">Netflix&#8217;s first-quarter earnings report,</a> where the company reported a revenue of $9.37 billion, up 14.8%, beating a Street consensus estimate of $9.275 billion. This report also revealed that Netflix added 9.33 million paid subscribers, surpassing expectations.
However, just a week before the earnings report, an analyst from Piper Sandler<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38228178/netflix-q1-subscriber-estimates-too-high-analyst-cautions-on-elevated-expectations-"> cautioned about inflated expectations</a> for Netflix&#8217;s Q1 subscriber numbers.
Price Action: On Thursday, Netflix closed at $610.56, 0.51% lower than its previous close. It was trading at $581.49 in the after-hours market.
Read Next: <a href="https://www.benzinga.com/news/24/04/38285714/no-more-inventory-discounts-on-tesla-cars-as-ceo-elon-musk-says-sales-system-has-turned-complex-and?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">No More Inventory Discounts On Tesla Cars As CEO Elon Musk Says Sales System Has Turned &#8216;Complex And Inefficient&#8217;</a>
Photo by freestocks on Unsplash
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Entertainment

General

NFLX

Netflix Is Dumping Quarterly Subscriber Reports: Co-CEO Greg Peters Says This Is What Motivated The Change

LIFW

Reported Earlier, LifeWallet Strikes Settlement With 10 Affiliated P&C Insurers, Expanding Claims Processing In 15 States

NGMS

Reported Earlier, NeoGames And Aristocrat Secure Final Regulatory Nods For Acquisition Deal

Banco Latinoamericano (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLX#NYSE">BLX</a>) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.14 by 22.81 percent. The company reported quarterly sales of $72.600 million which beat the analyst consensus estimate of $57.810 million by 25.58 percent. This is a 22.64 percent increase over sales of $59.200 million the same period last year.

Earnings

Earnings Beats

Banco Latinoamericano Q1 2024 GAAP EPS $1.40 Beats $1.14 Estimate, Sales $72.600M Beat $57.810M Estimate

ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn&#39;s Disease

Reported Earlier, Takeda Announces U.S. FDA Approval Of ENTYVIO Subcutaneous Administration For Maintenance Therapy In Moderately To Severely Active Crohn's Disease

As Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) <a href="https://www.benzinga.com/markets/equities/24/04/38312639/tesla-stock-on-free-fall-ahead-of-crucial-q1-earnings-here-are-key-levels-to-watch" target="_blank" rel="noreferrer noopener">fell for a fifth straight session</a> on Thursday, breaching a significant psychological threshold, Cathie Wood&#8216;s Ark Investment Management ramped up its acquisition of the stock, while also bolstering its holdings in crypto-related exchange-traded funds.
Doubling Down On Tesla: Across its&nbsp;ARK Innovation ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>),&nbsp;ARK Autonomous Technology &amp; Robotics ETF&nbsp;(CBOE: ARKQ), and&nbsp;ARK Next Generation Internet ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>), Ark purchased 88,720 Tesla shares on Thursday, amounting to approximately $13.30 million based on Tesla&#8217;s closing price of $149.93.
Ark has been consistently accumulating Tesla shares for three consecutive sessions this week, accumulating a total of $26.89 million worth of shares.
This surge in buying activity comes amid Tesla facing downward pressure throughout the week, with analysts revising their estimates and price targets downward in anticipation of a disappointing earnings report next week. Concerns about the company&#8217;s recent announcement of significant&nbsp;layoffs,&nbsp;plans to seek shareholder approval for CEO&nbsp;Elon Musk&#8216;s compensation package, and uncertainties surrounding the potential deprioritization of the sub-$30,000 electric vehicle have all contributed to the stock&#8217;s weakness.
On Thursday, Tesla closed at its lowest level since January 25, 2023.
See Also:&nbsp;<a target="_blank" href="https://www.benzinga.com/money/best-etfs" rel="noreferrer noopener">Best ETFs To Buy Right Now</a>
Expanding Crypto Exposure: While Ark has been <a href="https://www.benzinga.com/markets/equities/24/04/38214834/cathie-woods-ark-invest-sells-20m-coinbase-shares-as-bitcoin-trades-over-70k-buys-palantir-sells" target="_blank" rel="noreferrer noopener">gradually reducing its exposure</a> to crypto-related stocks like Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), it refrained from trading these shares on Thursday. 
Instead, Ark augmented its positions in ETFs with crypto exposure.
<ul>
<li>ARKW bought 22,461 units of ARK 21Shares Active Ethereum Futures Strategy ETF (CBOE: ARKZ) valued at $823,645.</li>
<li>Ark&#8217;s ARK Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>) 490,751 units of its recently launched spot Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ETF, the ARK 21Shares Bitcoin ETF (CBOE: ARKB) valued at $31.19 million.</li>
<li>Ark&#8217;s ARKW added 42,800 Proshares Ether Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EETH#NYSE">EETH</a>) valued at $2.90 million.</li>
</ul>
ARKB, which commenced trading on Jan. 11, 2024, has appreciated by approximately 36%, riding on the coattails of Bitcoin&#8217;s rally, which has surged by about 34% since its inception.
On the other hand, ARKZ, an actively managed ETF launched by the Wood-led firm, aims for 100% exposure to&nbsp;Ethereum&nbsp;(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) by investing in ether futures contracts. The fund, boasting approximately $11 million in net assets, has yielded approximately 24% year-to-date.
Meanwhile, Bitcoin has strengthened amid escalating geopolitical tensions in the Middle East. At last check, the premier cryptocurrency climbed by 0.72% over the past 24 hours to reach $62,141.40, according to&nbsp;<a target="_blank" href="https://benzinga.grsm.io/lxquj26b2sag" rel="noreferrer noopener">Benzinga Pro data.</a>
ARKK fell 0.26% on Thursday before closing at $42.91.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37891092/5-technologies-that-could-be-worth-220-trillion-by-2030-cathie-woods-ark-predicts-t">5 Technologies That Could Be Worth $220 Trillion By 2030, Cathie Wood&#8217;s ARK Predicts: &#8216;The Time Is Now&#8217;</a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Long Ideas

Specialty ETFs

Trading Ideas

ETFs

$BTC

$ETH

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

ARKF

ARKK

ARKQ

ARKW

ARKZ

COIN

EETH

HOOD

Cathie Wood Sees Value In Tesla Wreckage As Ark Buys $13M Worth Of EV Giant's Stock, Loads Up On Bitcoin And Ethereum ETFs

Changpeng Zhao, the former CEO of Binance, recently clarified that Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/money/what-is-bitcoin-halving">halving</a> is not akin to a stock split, emphasizing the nascent stage of cryptocurrency understanding.
What Happened: On Friday, Changpeng Zhao took to X, formerly Twitter, to address a question about Bitcoin halving. He stated, &#8220;Someone asked me if bitcoin halving is like a stock split&#8230; We are still early. (Answer is no) Happy halving!&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Someone asked me if bitcoin halving is like a stock split&#8230; We are still early. (Answer is no) Happy halving! <a href="https://t.co/gxAvfOpGQH">pic.twitter.com/gxAvfOpGQH</a>
&mdash; CZ &#x1f536; BNB (@cz_binance) <a href="https://twitter.com/cz_binance/status/1781180083425988959?ref_src=twsrc%5Etfw">April 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Zhao, shared his earlier thoughts on halving dated Oct. 9, 2023. The Binance founder reflected on Bitcoin halvings based on his past experiences with the event. 
He said that in the months leading up to the halving, there was typically increased discussion, news coverage, anxiety, and anticipation surrounding Bitcoin.
However, immediately after the halving, the price of Bitcoin didn&#8217;t skyrocket overnight. Despite this, in the year following the halving, Bitcoin&#8217;s price often reached multiple all-time highs, prompting people to wonder about the reasons behind it. Zhao emphasized that while there may not be proven causation between halvings and price movements, history doesn&#8217;t necessarily predict the future.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38284502/dogecoin-killer-shiba-inu-sees-significant-increase-in-token-burn-rate-as-price-recovers-i?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Dogecoin Killer&#8217; Shiba Inu Sees Significant Increase In Token Burn Rate, As Price Recovers — Is A Turnar</a>
Why It Matters: Bitcoin halving is a pre-programmed mechanism that fundamentally impacts the economics of mining and potentially shapes the future price and ecosystem of Bitcoin. The upcoming halving event, the fourth of its kind, is scheduled for around April 20, 2024. This event will slash Bitcoin miner rewards from 6.25 BTC to 3.125 BTC.
Contrary to a stock split, which increases the number of shares of a company without changing its market capitalization, Bitcoin halving reduces the rate at which new tokens are created, effectively limiting the cryptocurrency&#8217;s supply. This fundamental difference underlines Zhao&#8217;s clarification and the importance of understanding the unique dynamics of cryptocurrency.
Price Action: At the time of writing, Bitcoin traded 1.2% higher at $61,961.16, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data. </a>
Photo Courtesy: Wikimedia Commons
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38299089/trump-related-maga-memecoin-onboards-roger-stone-as-partner?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump-Related MAGA Memecoin Onboards Roger Stone As Partner</a>
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Shivdeep Dhaliwal</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Is Bitcoin Halving Like A Stock Split? Binance Founder Changpeng Zhao Says 'No' — Offers Insights On Post-Event Dynamics

With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
Wall Street expects The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) to report quarterly earnings at $1.41 per share on revenue of $20.41 billion before the opening bell, according to data from Benzinga Pro. Procter &amp; Gamble shares fell 0.1% to $157.14 in after-hours trading.
Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) reported better-than-expected results for its first quarter on Thursday. Intuitive Surgical shares gained 3.5% to $385.60 in the after-hours trading session.
Analysts are expecting American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) to post quarterly earnings at $2.95 per share on revenue of $15.79 billion. The company will release earnings before the markets open. American Express shares fell 1.7% to $213.90 in after-hours trading.
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported upbeat earnings and sales results for its first quarter. The company added 9.33 million paid net new subscribers in the first quarter to bring the company to a total of 269.60 million. Netflix shares fell 4.8% to $581.49 in the after-hours trading session.
Analysts expect Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) to post quarterly earnings at 75 cents per share on revenue of $8.69 billion before the opening bell. SLB shares fell 0.5% to $50.69 in after-hours trading.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/04/38285336/how-to-earn-500-a-month-from-intel-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Intel Stock Ahead Of Q1 Earnings</a>

Pre-Market Outlook

ISRG

Netflix, Procter & Gamble And 3 Stocks To Watch Heading Into Friday

The CNN Money Fear and Greed index showed a slight decline in the overall market sentiment, while the index remained in the &#8220;Fear&#8221; zone on Thursday.
U.S. stocks closed mixed on Thursday, with the S&amp;P 500 falling for a fifth straight session. All major indices are also on course to record losses this week, with the S&amp;P 500 falling more than 2% so far during the week.
On the economic data front, U.S. initial jobless claims came in unchanged from the previous week at 212,000 for the week ending April 18, down from market expectations of 215,000. The Philadelphia Fed Manufacturing Index increased 12 points to a reading of 15.5 in April, topping market estimates of 1.5.
D.R. Horton, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) reported better-than-expected second-quarter financial results. After the closing bell, Netflix Inc  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported upbeat earnings and sales results for its first quarter.
Most sectors on the S&amp;P 500 closed on a positive note, with communication services, utilities and consumer staples stocks recording the biggest gains on Thursday. However, information technology and consumer discretionary stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 22 points to 37,775.38 on Thursday. The S&amp;P 500 fell 0.22% at 5,011.12, while the Nasdaq Composite dipped 0.52% at 15,601.50 during Thursday's session.
Investors are awaiting earnings results from The Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) and Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) today.
At a current reading of 34.1, the index remained in the &#8220;Fear&#8221; zone on Thursday, versus a prior reading of 34.3.
What is CNN Business Fear &amp; Greed Index?
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38312296/jim-cramer-recommends-buying-ethereum-or-bitcoin-instead-of-this-stock-lets-not-fool-aro">Jim Cramer Recommends Buying Ethereum Or Bitcoin Instead Of This Stock: &#8216;Let&#8217;s Not Fool Around&#8217;</a>

Investor Optimism Edges Lower; S&P 500 Settles Lower For Fifth Session

American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) is expected to release earnings results for its first quarter, before the <a href="https://www.benzinga.com/quote/AXP/earnings">opening bell on April 19, 2024</a>.
Analysts expect the New York-based company to report quarterly earnings at $2.95 per share, up from $2.19 per share in the year-ago quarter. American Express is projected to report quarterly revenue of $15.79 billion, compared to $13.05 billion in the year-earlier period, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
CLEAR recently extended its partnership with American Express to deliver premium value to members and enhance airport experience.
American Express shares fell 0.1% to close at $217.50 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/AXP/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>HSBC analyst Saul Martinez maintained a Buy rating and boosted the price target from $232 to $239 on April 11, 2024. This analyst has an accuracy rate of 65%.</li>
<li>Wells Fargo analyst Donald Fandetti maintained an Overweight rating and increased the price target from $220 to $250 on April 10, 2024. This analyst has an accuracy rate of 71%.</li>
<li>UBS analyst Eric Wasserstrom maintained a Neutral rating and boosted the price target from $188 to $206 on Jan. 29, 2024. This analyst has an accuracy rate of 75%.</li>
<li>BMO Capital analyst James Fotheringham maintained an Underperform and raised the price target from $157 to $159 on Jan. 29, 2024. This analyst has an accuracy rate of 73%.</li>
<li>Baird analyst David George downgraded the stock from Neutral to Underperform with a price target of $190 on Jan. 8, 2024. This analyst has an accuracy rate of 74%.</li>
</ul>
Read This Next: <a href="https://www.benzinga.com/news/24/04/38268727/top-4-tech-stocks-you-may-want-to-dump-in-april">Top 4 Tech Stocks You May Want To Dump In April</a>

Price Target

American Express Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

HMN Financial(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HMNF#NASDAQ">HMNF</a>) reported quarterly earnings of $0.30 per share. This is a 18.92 percent decrease over earnings of $0.37 per share from the same period last year. The company reported $9.16 million in sales this quarter. This is a 8.29 percent decrease over sales of $9.99 million the same period last year.

HMNF

HMN Financial Q1 EPS $0.30 Down From $0.37 YoY, Sales $9.16M Down From $9.99M YoY

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) has taken down Meta Platforms&#8217; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) applications, WhatsApp and Threads, from its China App Store, in response to a Chinese government order.
What Happened: The Chinese government&#8217;s directive specifically targeted WhatsApp and Threads, without providing a detailed explanation of the perceived security threat, Reuters reported on Friday. Other Meta apps including Facebook, Instagram, and Messenger remain accessible in the China App Store.
Apple, in an email statement to Reuters, said, &#8220;The Cyberspace Administration of China ordered the removal of these apps from the China storefront based on their national security concerns. We are obligated to follow the laws in the countries where we operate, even when we disagree.&#8221;
At the time of publishing this article, a Meta spokesperson referred to Apple for further comments while Apple has yet to respond to the queries sent by <a href="https://pro.benzinga.com">Benzinga</a>.
See Also: <a href="https://www.benzinga.com/news/24/04/38288119/chinese-fighter-jets-shadow-us-navy-aircraft-over-taiwan-strait-amid-escalating-tensions-will-resolu?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Chinese Fighter Jets Shadow US Navy Aircraft Over Taiwan Strait Amid Escalating Tensions: &#8216;Will Resolutely Defend National Sovereignty And Security&#8230;&#8217;</a>
Why It Matters: This development follows a <a href="https://www.benzinga.com/markets/asia/23/10/35087405/apple-yields-to-chinese-regulations-developers-now-need-government-license-for-app-store-access">new regulation introduced last August, </a>mandating all apps in China to register with the government or face removal. The deadline for registration was the end of March, and the rules came into effect on Apr. 1. 
Apple has previously removed apps from its China App Store, including The New York Times news app in 2017, and several ChatGPT-like apps in 2021. Apple had initially resisted the Chinese government&#8217;s rules for app stores but eventually complied.
Apple&#8217;s CEO, Tim Cook, recently visited China, a move that analysts suggest could indicate Apple&#8217;s intention to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37927675/tim-cooks-latest-visit-a-sign-apple-could-double-down-on-china-says-analyst-as-ipho">double down on its presence in the country</a>, despite regulatory pressures and declining sales. 
Meanwhile, Meta has faced its own share of challenges in China, partially due to CEO Mark Zuckerberg&#8217;s <a href="https://www.benzinga.com/government/23/07/33097839/mark-zuckerbergs-chants-against-china-proves-costly-for-his-metaverse-ambitions-in-country">unfavorable image in the country</a>.
The removal of the apps comes amid increasing tensions between the U.S. and China, with the U.S. House of Representatives recently<a href="https://www.benzinga.com/markets/asia/24/03/37800098/tiktok-ban-china-has-the-power-to-block-sale-gains-leverage-over-washington"> moving forward on a bill that could ban TikTok</a> in the U.S. unless sold by its owner, ByteDance Ltd.
Price Action: On Thursday, Apple closed 0.57% lower than its previous close at $167.04 while Meta closed at $501.80, indicating a 1.54% increase since its previous close.
Read Next: <a href="https://www.benzinga.com/markets/24/04/38274667/prudent-investors-pay-attention-to-the-extraordinary-treasuries-move-momo-obliviously-buys-stocks?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Prudent Investors Pay Attention To The Extraordinary Treasuries&#8217; Move – Momo Obliviously Buys Stocks</a>
Photo by James Yarema on Unsplash
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Social Media

Global

Apple Bows To China's Security Concerns: Pulls 2 Meta Products From App Store

Macro Economic Events

Econ #s

Economics

Germany Producer Price Index (MoM) For March 0.2% Vs. 0.0% Est.; -0.4% Prior

U.K. Retail Sales (MoM) For March 0.0% Vs. 0.3% Est.; 0.1% Prior

U.K. Retail Sales (YoY) For March 0.8% Vs. -0.3% (Revised) Prior

Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) is set to release earnings results for its first quarter before the <a href="https://www.benzinga.com/quote/SLB/earnings">opening bell on April 19, 2024.</a>
Analysts expect the Houston, Texas-based company to report quarterly earnings at 75 cents per share, up from 63 cents per share in the year-ago period. SLB is projected to report quarterly revenue of $8.69 billion, compared to $7.74 billion in the year-earlier quarter, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
SLB recently announced an agreement to acquire ChampionX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHX#NYSE">CHX</a>) in an all-stock transaction. Schlumberger will acquire ChampionX, and the shareholders will receive 0.735 shares of Schlumberger in exchange for each ChampionX share.
SLB shares rose 0.3% to close at $50.94 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/SLB/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Susquehanna analyst Charles Minervino maintained a Positive rating with a price target of $77 on April 8, 2024. This analyst has an accuracy rate of 65%.</li>
<li>Barclays analyst David Anderson maintained an Overweight rating and cut the price target from $74 to $70 on April 4, 2024. This analyst has an accuracy rate of 69%.</li>
<li>Goldman Sachs analyst Neil Mehta maintained a Buy rating on April 1, 2024. This analyst has an accuracy rate of 71%.</li>
<li>Wells Fargo analyst Roger Read maintained an Overweight rating and boosted the price target from $69 to $70 on Jan. 22, 2024. This analyst has an accuracy rate of 74%.</li>
<li>Raymond James analyst James Rollyson maintained an Outperform rating and increased the price target from $68 to $72 on Oct. 23, 2023. This analyst has an accuracy rate of 71%.</li>
</ul>
Also Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38321908/top-3-consumer-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Consumer Stocks Which Could Rescue Your Portfolio This Quarter</a>

Schlumberger Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Biology is the study of life. And synthetic biology is the creation of new life for new purposes. Ever since the Green Revolution of the 1970s, synthetic biology has allowed us to make new crops, drugs, and additives for profit and to make the world a better place.
But the true promise of synthetic biology is still to come. Many drugs and products are still made chemically, but can instead be made with synthetic biology. Many novel organisms can be used for research or industrial purposes. And the rewards of wealth still await the investors who can understand the science and finance of the best synthetic biology stocks to buy now.
It&rsquo;s also critical to understand the breadth of synthetic biology in today&rsquo;s market. Synthetic biology is so much more than DNA stocks. It includes hundreds of companies making new organisms for new purposes. It has spread across nearly every industry sector that uses biology at all. Thus, the synthetic biology revolution is not a small part of the stock market anymore.
Although synthetic biology stocks had a poor 2022, a new year is still ahead, and the future looks bright for the industry. Don&rsquo;t write all synthetic biology stocks off just because the <a href="https://investorplace.com/stock-types/meme-stocks/">meme stocks</a> crashed and burned! Here are 3 DNA stocks to buy for the synthetic biology revolution.

<a href="https://investorplace.com/stock-quotes/txg-stock-quote/">TXG</a>
10x Genomics
$52.64
<a href="https://investorplace.com/stock-quotes/crl-stock-quote/">CRL</a>
Charles River Laboratories
$191.24
<a href="https://investorplace.com/stock-quotes/twst-stock-quote/">TWST</a>
Twist Bioscience
$11.95

<h2>10x Genomics (TXG)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2020/03/gene_editing_a_1600-300x169.jpg" alt="Gene editing stocks: a concept image of a hand holding a pair of tweezers that is pulling a section off of a dna strand" width="300" height="169"><div>Source: vxhal/ShutterStock.com</div></div>
10x Genomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/txg-stock-quote/">TXG</a>) specializes in the study of single cell genomics. Although all the cells in our body contain the same DNA, that DNA is stored, read, and used differently in different cells. That is what allows muscle cells to develop and act differently than nerve cells. And 10x Genomics gives researchers a window in the world of each individual cell in a body.
10x Genomics allows scientists to sequence the DNA or RNA of millions of cells across multiple different dimensions simultaneously. That allows researchers to study how cells react to drugs across multiple avenues. It also allows researchers to spot why a drug may work for some cells and not others, as well as how to fix that.
10x Genomics stock fell hard during the biotech crash of 2022, but has been recovering since then. Their <a href="https://s28.q4cdn.com/592666581/files/doc_financials/2023/q1/c15e0c95-b939-4312-9c71-e37e7211b314.pdf">Q1 2023 earnings</a> show a company with growing revenue, and the cash on hand to continue losing money at their current pace for a while yet.
Genetic sequencing is only going to get more important as drug screens become more and more complex. Scientists are now making completely new cells, of multiple types, to assist in studying how drugs will react inside our bodies. And every cell is tested across multiple genetic avenues. More and more drug companies are entering the world of Big Genomics, and that&rsquo;s exactly why they&rsquo;ll be working with 10x Genomics.

<h2>Charles River Laboratories (CRL)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2021/08/laboratory-scientist-1600-300x169.jpg" alt="scientist wearing virtual reality headset interacts with futuristic holographic interface showing neurological data" width="300" height="169"><div>Source: Gorodenkoff / Shutterstock</div></div>
Charles River Laboratories (NYSE:<a href="https://investorplace.com/stock-quotes/crl-stock-quote/">CRL</a>) is a Contract Research Organization (CRO) that specializes in making other companies&rsquo; synthetic biology dreams into a reality. The company provides services for <a href="https://www.criver.com/products-services/research-models-services/genetically-engineered-model-services?region=3601">making and testing</a> any new genetically modified species to suit a client&rsquo;s needs. Scientists often want to study an animal that is specifically tailored to model a human disease or condition. Charles River&rsquo;s technology allows for more accurate results when performing drug screens against that condition than when using naturally-evolved animals.
Charles River also sells its contract research services to other synthetic biology companies. Many companies have a will, but not the way to perform complex synthetic biology. Charles Rivers has the synthetic biology expertise to help those companies. This provides a niche, allowing the company to profit off the entire synthetic biology industry, rather than being tied down to a single drug or pipeline.
It may seem unglamourous, but a CRL stock is a much safer play than investing directly in a smaller synthetic biology company. Whenever someone invents a new drug, they&rsquo;ll need someone to help them screen it, make it at scale, and test it for purity. Charles river is that someone.
The company&rsquo;s <a href="https://ir.criver.com/static-files/8ae49c45-37d8-4184-94c9-74cf511974a0">Q1 2023 earnings</a> highlighted $4 billion in revenue and $489 million in net income. Demand for the company&rsquo;s services will only increase with the continued rise of synthetic biology. It&rsquo;s best to get in early in cases such as this.

<h2>Twist Bioscience (TWST)</h2>
<div><img src="https://investorplace.com/wp-content/uploads/2022/11/twst1600-300x169.png" alt="Scientific handling a light microscope examines a laboratory sample for pharmaceutical bioscience research. Concept of science, laboratory and study of diseases. Twist Biosciences (TWST)" width="300" height="169"><div>Source: dhvstockphoto / Shutterstock.com</div></div>
Among DNA stocks, Twist Bioscience (NASDQ:<a href="https://investorplace.com/stock-quotes/twst-stock-quote/">TWST</a>) stands above the rest in terms of price. It offers to sell DNA at a cost as low as <a href="https://www.twistbioscience.com/products/genes">7 cents</a> per base pair, far below competitors like Genscript (OTCMKTS:<a href="https://investorplace.com/stock-quotes/gnnsf-stock-quote/">GNNSF</a>) and Azenta (NASDAQ:<a href="https://investorplace.com/stock-quotes/azta-stock-quote/">AZTA</a>). DNA is the fundamental ingredient of synthetic biology. And Twist is positioned to sell more of it than anyone else.
DNA may seem like simple stuff, but don&rsquo;t be fooled. For any single new organism that gets commercialized, there were thousands of organisms that had to be created and tested. And for each organism created, a specific genetic library must be purchased to create it. Demand for novel DNA will continue to increase as more synthetic biology companies are created. And Twist&rsquo;s price means it can sell to all of them.
Like other synthetic biology companies, Twist&rsquo;s stock took a beating in 2022. However, unlike many of its peers, the beatings haven&rsquo;t let up in 2023. Still, the company&rsquo;s <a href="https://investors.twistbioscience.com/static-files/ab61e0e9-9226-4307-89ed-0d667252d936">Q1 2023 earnings</a> have given reason to be hopeful. With 25% revenue growth year-over-year ($48 million to $60 million), they&rsquo;re making headway. And with $315 million in cash and cash equivalents with $61 million in net loss, they can keep this burn rate for some time yet.
While Twist may be a speculative play, they&rsquo;ve got the runway needed to fly. And that makes Twist one of the most enticing synthetic biology companies of 2023.
On the date of publication, John Blankenhorn did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>
John Blankenhorn is a neuroscientist at Emory University. He has significant experience in biochemistry, biotechnology and pharmaceutical research.
</div>
<h3>More From InvestorPlace</h3>
<ul><li>
						<a href="https://investorplace.com/2022/07/little-known-apple-project/?cid=MKT639809&amp;eid=MKT653131">Buy This $5 Stock BEFORE This Apple Project Goes Live</a>
					</li>
<li>
						<a href="https://investorplace.com/2022/06/this-could-be-the-best-deal-in-the-history-of-independent-investing-research/?cid=MKT638063&amp;eid=MKT644740">The Best $1 Investment You Can Make Today</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/04/one-of-the-worlds-biggest-tech-breakthroughs-could-be-happening-in-americas-heartland/?cid=MKT714907&amp;eid=MKT731269">Wall Street Titan: Here&rsquo;s My #1 Stock for 2023</a>
					</li>
<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT513141">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
</ul><div>
<div>
<div></div>
<div></div>
</div>
</div>

The post <a href="https://investorplace.com/2023/05/3-dna-stocks-to-buy-for-the-synthetic-biology-revolution/">3 DNA Stocks to Buy for the Synthetic Biology Revolution</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 DNA Stocks to Buy for the Synthetic Biology Revolution

GenScript Biotech Corporation (GNNSF) Q2 2023 Earnings Call Transcript

In a report released yesterday, Chris Lui from Jefferies maintained a Buy rating on Genscript Biotech (GNNSF – Research Report), with a price targe...

Jefferies Sticks to Their Buy Rating for Genscript Biotech (GNNSF)

Jefferies analyst Chris Lui maintained a Buy rating on Genscript Biotech (GNNSF – Research Report) yesterday and set a price target of HK$30.00. Th...